MANAGEMENT OF PRIMARY & SECONDARY BREAST LYMPHOMA

Amari Jellali, Ines Zermi, Takoua Chaloussi, Sara Ben Ltaief, Fatma Saadallah, Riadh Chargui, Khhaled Rahal. Department of surgical oncology, Salah Azaiez Institute, Tunisia, Tunisia

10.1136/ijgc-2022-ESGO.470

Introduction/Background Breast lymphomas are extremely rare malignancies in both genders, especially in men. They can be either primary or secondary. Primary ones are malignant lymphomas that occur in the breast without previously detected lymphomas. Their reported incidence is 0.04% of all breast malignancies. We aimed to discuss the clinical aspect, the anatopmorphological characteristic, and the evolution of this rare entity.

Methodology We report seven cases of breast lymphomas followed up at Salah Azaiez institute of oncology in Tunis.

Results The median age at the diagnosis of breast lymphoma was 49 years. Six patients were female. The mean tumor size was 33 mm. Inflammatory breast tumor was noticed in one case, while six patients presented a palpable mass. Breast imaging revealed suspicious lesions classified as BIRADS 5 in all cases. Microbiopsy was performed in all cases. Secondary lymphoma was found in six patients (3 high-grade B cell lymphomas, 3 Hodgkin lymphomas), while primary one was noted in a male breast patient. Neoadjuvant chemotherapy followed by a modified radical mastectomy was performed in one case. 6 patients had chemotherapy. Two of them had 2 years of follow-up with no sign of recurrence. One patient had local recurrence. The rest of patients were lost of follow-up.

Conclusion There is no therapeutic consensus because of the rarity and heterogeneity of primary breast lymphomas. Treatment for breast lymphoma is based upon the overall staging of the lymphoma and generally requires chemotherapy, surgery, and radiation therapy.

ONCOLOGICAL OUTCOMES OF UNEXPECTED UTERINE LEIOMYOSARCOMAS: A SINGLE CENTRE RETROSPECTIVE ANALYSIS

1Vincenzo Granato, 2Giorgio Bogani, 3Antonio Lembo, 4Emanuele Filippo Galati, 5Fabio Ghezzi, 1Ivan Casarin. 1University of Insubria, Ospedale di Circolo Fondazione Macchi, Varese, Italy; 2Department of Maternal and Child Health and Urological Sciences, Sapienza University, Policlinico Umberto I, Rome, Italy; 3Ospedale di Circolo Fondazione Macchi, Varese, Italy

10.1136/ijgc-2022-ESGO.471

Introduction/Background Uterine leiomyosarcomas (LMS) are the most frequent uterine sarcomas and about 43% of them are diagnosed after hysterectomy performed for presumed benign disease. The incidence of unexpected LMS can reach 0.49%. The purpose of this study is to report the oncological outcomes of patients who had incidental finding of unexpected LMS following hysterectomy and compare them to those of women who had surgery for suspected LMS.

Methodology A retrospective study was conducted on 5,528 consecutive patients who underwent hysterectomy at the Filippo del Ponte hospital of Varese from 2000 to 2019. Baseline characteristics, relapse rate and pattern of recurrence were analysed by stratifying the population in suspicious/unexpected LMS. The oncologic outcomes and risk factors, including surgical approach were analysed. Risk factor for LMS were also evaluated.

Results Among 4428 suspect benign cases, 24 unexpected LMS were found (0.54%). Malignancy was preoperatively suspected in 1,100 cases and 12 LMS were found at final histology (1.09%). Baseline characteristics did not differ between the groups. In the unexpected-LMS group, 15 (62.5%) patients had laparoscopic approach (LPS), 14 (58.3%) had morcellation and 2/14 (14.3%) was contained. In the suspect group 9 (75%) of patients underwent open surgery, 3 (25%) LPS were performed, 1 had in-bag morcellation. In the comparison between unexpected vs. suspicious LMS, no factors influencing prognosis were identified. Among patients who had laparoscopic approach, a higher rate of loco-regional relapse was found (LPS 78% vs. Open 33.3%, p = 0.04).

Abstract 2022-RA-1659-ESGO Table 1 Surgical approach

<table>
<thead>
<tr>
<th>Type of surgery</th>
<th>Suspicious</th>
<th>Unexpected</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of surgery</td>
<td>n=12</td>
<td>n=24</td>
<td></td>
</tr>
<tr>
<td>Laparoscopy</td>
<td>3 (25%)</td>
<td>15 (62.5%)</td>
<td></td>
</tr>
<tr>
<td>Open surgery</td>
<td>9 (75%)</td>
<td>9 (37.5%)</td>
<td></td>
</tr>
<tr>
<td>BSO</td>
<td>12 (100%)</td>
<td>21 (87.5%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Lymphadenectomy</td>
<td>2 (16.67%)</td>
<td>0 (0%)</td>
<td>0.10</td>
</tr>
</tbody>
</table>

EXTRACTION

<table>
<thead>
<tr>
<th>Type of surgery</th>
<th>Suspicious</th>
<th>Unexpected</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of surgery</td>
<td>n=12</td>
<td>n=24</td>
<td></td>
</tr>
<tr>
<td>Morcellation</td>
<td>1 (8.33%)</td>
<td>14 (53.3%)</td>
<td>0.005</td>
</tr>
<tr>
<td>In bag</td>
<td>1/1 (100%)</td>
<td>2/14 (14.29%)</td>
<td>1</td>
</tr>
<tr>
<td>Mini-LPT2</td>
<td>1 (8.33%)</td>
<td>1 (4.17%)</td>
<td>0.31</td>
</tr>
<tr>
<td>LDH</td>
<td>349 (188-585)</td>
<td>357 (164–1378)</td>
<td>0.23</td>
</tr>
<tr>
<td>Uterus weight (gr)</td>
<td>550 (200–6000)</td>
<td>650 (60–2500)</td>
<td>0.52</td>
</tr>
</tbody>
</table>

1Bilateral Salpingo-Oophorectomy 2Mini-Laparotomy

Conclusion The incidence of unexpected LMS in women undergoing hysterectomy for benign disease was 1/185 (0.54%). The preoperative malignant suspicion in patients undergoing total hysterectomy with subsequent LMS diagnosis did not affect the oncological outcomes. No predictors of relapse were identified. LPS was associate to higher rates of loco-regional relapse. Increased age, uterine weight and menopausal status were associated with higher risk of LMS.

THE DIGITAL TRANS-AFRICAN E-HEALTH NETWORK: A CLINICAL PARTNERSHIP EXPERIENCE

1Sara Nasser, 2Jalid Sehouli, 3Karim Loret-Hassan, 4Pierre Adegne Togo, 5Adil Elghanmi, 6Andrew Ullrich, 7Andreas Kaufmann, 8Gynecological Oncology and Tumor Surgery, Charite Comprehensive Cancer Center, Berlin, Germany; 9Pan-Arabian Research Society for Gynecologic Oncology, Berlin, Germany; 10Hopital Gabriel Toure, Bamako, Mali; 11Mohammed VI University, Casablanca, Morocco; 12Charite Comprehensive Cancer Center, Berlin, Germany

10.1136/ijgc-2022-ESGO.472

Introduction/Background In a globalised world, digital platforms have become pivotal to overcome training and
healthcare-access inequalities in low-and middle in countries (LMICs). The Trans-African digital e-Health network was established as a capacity-building partnership project between Mali, Morocco and Germany to improve the women’s cancer care.

The mainstay of this project is education and training of healthcare professional using digital solutions. A two-day summer school was held to strengthen this digital network.

We report on the event and analyse the results of the live-poll questions.

**Methodology** The hybrid summer school event was held in May 2022, hosted by Charite. It covered the main themes of: Screening/Prevention, Treatment and Research/Innovation for cervical and breast cancer. Within each session, online participants were asked to fill out several poll questions. The results were used live as a basis for discussion.

**Results** A total of 314 participants registered for the event from nearly 100 countries worldwide. Germany was the country with the highest number of participants. Participation rate was 40.1%. A total of 13 poll questions were asked and discussed live. Based on the anonymous live answers majority of participating countries specified they had a national screening policy for cervical cancer and just more than half had an HPV vaccination program (82% and 56% respectively). In 64% of respondents HPV vaccination was not available for boys. 71% of respondents did not have official gyn-oncology training programs in their countries and 67% stated they could not/not did not recruit to clinical trials due to lack of availability. Although 88% stated they would recruit if trials were more accessible in their country or region.

**Conclusion** Building sustainable digital pan-regional networks on the basis of clinical partnerships is an effective strategy for increasing knowledge exchange and long-term impact on the standards of care within LMICs regardless of local resources.

**2022-RA-1684-ESGO PRIMARY NEUROENDOCRINE TUMORS OF THE BREAST: A SERIES OF FIVE CASES**

Amani Jellali, Saida Sakhti, Takoua Chalouati, Ma adolescence Bouchani, Sarra Ben Ltaief, Riadh Chargui, Khaled Rahal, Khaled Rahal. Department of surgical oncology, Salah Azaiez Institute, Tunisia, Tunisia

10.1136/ijgc-2022-ESGO.473

**Introduction/Background** Neuroendocrine neoplasms (NE) are uncommon heterogeneous tumors that arise from neuroendocrine cells all over the body. Breast primary NE tumors are sporadic and extremely rare entities, accounting for 0.1% of all breast cancers and less than 1% of all neuroendocrine tumors.

**Methodology** We report a series of five patients treated, at Salah Azaiez Institute from 2012 to 2022.

**Results** We present five cases with an average age of 59.8 years. They presented with a single breast mass in four cases and multiple breast mass in one case. Physical examination revealed mobile, non-tender firm lesions. The average size of the tumor was 25 mm. In one case, mammography and ultrasonography revealed suspicious lesions classified as BIRADS 5. The tumor was classified as BIRADS 4c in one case. Chest, abdomen and pelvis scan revealed no evidence of distant metastases in all cases. Microbiopsy was performed prior to surgery in three cases. Breast conserving surgery was performed in three cases and modified radical mastectomy in the two others. In all cases, the final pathology study concluded to a neuroendocrine carcinoma with no metastatic lymph nodes. On immunohistochemical evaluation, the tumor cells stained strongly positive for estrogen and progesterone receptors (in two cases) and were positive for synaptophysin (all cases), also for chromogranin (in three cases). Two patients received adjuvant radiotherapy; one patient had chemotherapy only, while chemotherapy and radiotherapy associated to hormonal therapy were given to the two others. The mean time of follow-up was 21.8 months, and there were no recurrence or distant metastases noticed.

**Conclusion** Due to their rarity and heterogeneity, primary breast neuroendocrine tumors are underappreciated. They have a poor prognosis. There are no specific treatment guidelines, and the available data is primarily based on case reports.

**2022-RA-1686-ESGO PURE DUCTAL CARCINOMA IN SITU IN THE MALE BREAST: AN UNCOMMON ENTITY**

Amani Jellali, Saida Sakhti, Takoua Chalouati, Malek Bouchani, Sarra Ben Ltaief, Olfa Jaidane, Khaled Rahal. Department of surgical oncology, Salah Azaiez Institute, Tunisia, Tunisia

10.1136/ijgc-2022-ESGO.474

**Introduction/Background** Ductal carcinoma in situ (DCIS) in males is an uncommon occurrence that is usually associated with invasive carcinoma. Male breast DCIS is exceedingly rare, accounting for 0.1% of all breast cancers and 5% of male ones. The aim of this study is to highlight the relevance of this condition in males and to assess the treatment options for this uncommon malignancy.

**Methodology** We retrospectively report four cases of pure ductal carcinoma in situ in the male breast treated at Salah Azaiz Institute from 2012 to 2022.

**Results** The average age of DCIS was 53.5 years with a mean delay of consultation of 73 days (21–152 days). The symptoms were essentially a retroareolar breast mass (in three cases), nipple retraction (in one case) and unipore bloody discharge (in one case). Gynecomastia was observed in two patients. The main radiological findings were nodules. Microcalcifications were noticed on one case. The median size of the tumor was 25 mm. Two patients had an ipsilateral axillary lymph node. The left side was in 3 cases. All of the patients underwent surgery: three patients had mastectomy and sentinel lymph node and one patient had mastectomy with lymph node dissection. The definitive histopathological assessment showed DCIS associated with papillary, cribriform, and comedocarcinoma in situ. There was no evidence of invasive carcinoma. In one case, the DCIS was associated with Paget’s disease of the nipple. Two patients received adjuvant hormonotherapy (Tamoxifen). The mean time of follow-up was 75.5 months. One patient developed an invasive recurrence after 6 months of surgery.

**Conclusion** Treatments for males with DCIS have been mostly extrapolated from studies on female breast cancer due to the lack of data. Mastectomy with lymph node sampling is the standard treatment. Hormonotherapy can be recommended based on the hormonal receptors status.